Articles

Melissa Barnett, OD, from the University of California, Davis Eye Center, Sacramento and Davis, CA, described new strategies, technologies, and drug classes to treat chronic conditions that include myopia, Demodex infestation, meibomian gland dysfunction, glaucoma drug delivery, advancements in corneal and cataract surgeries, and presbyopia

Eye care therapies on the move: What’s in the pipeline

Videos

Brandon Barber, chief marketing officer at Heru, shares about the company's new dark adaptation modality, which they announced during the 2022 Vision Expo West, as well as other advancements in the pipeline.

VEW 2022: New dark adaptation modality and other pipeline updates from Heru

Azura has secured funding to support its 2-stage study evaluating the safety, tolerability, and efficacy of AZR-MD-001, its leading candidate, for patients with contact lens discomfort who show signs of meibomian gland dysfunction.

Azura Ophthalmics receives grant for leading CLD clinical candidate

Brad Sutton, OD, FAAO, FORS, shares highlights from his SCOPA 2022 presentation, "Topical Pharmacology Rounds."

SCOPA 2022: A review of topical medication classes in eyecare

Latest data from phase 3 studies finds increased effects over time with intravitreal pegcetacoplan for geographic atrophy secondary to age-related macular degeneration.  

Apellis releases 24-month results of phase 3 studies for GA treatment

Latest transaction, totaling approximately $770 million, adds key commercial products and clinical/preclinical product candidates in the pipeline. 

Alcon to acquire Aerie Pharma, expanding ophthalmic pharma portfolio

Ranibizumab-eqrn will offer greater treatment access and choice for patients, payors, and providers in the US.

FDA approves biosimilar product ranibizumab-eqrn for retinal diseases 

COMET-3 is the second of 3 studies in the AR-15512 Registrational Phase 3 Program, which is slated for completion by 2023. 

Aerie doses first patient in COMET-3 study for DED treatment

If approved, pegcetacoplan—an investigational, targeted C3 therapy—will be the first-ever treatment for GA.

Apellis receives FDA acceptance, priority review of NDA for GA treatment 

A comprehensive analysis of the possible directions corporate optical practices might be headed in.

Pipeline

Latest News